Real world outcomes of first line (1L) nivolumab and ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC): An update from the International mRCC Database Consortium (IMDC).
J. Connor Wells(Queen's University), Daniel Yick Chin Heng(University of Calgary), Ben Tran(The Royal Melbourne Hospital), Sumanta K. Pal(City of Hope), Arnoud J. Templeton(University of Basel), Renée Maria Saliby(Yale University), Toni K. Choueiri(Harvard University), Rana R. McKay(University of California San Diego), Audreylie Lemelin(University of Calgary), Lori Wood(Dalhousie University), Cristina Suárez(Complejo Hospitalario de Salamanca), Hedyeh Ebrahimi(Beth Israel Deaconess Medical Center), Guillermo de Velasco(Dana-Farber Cancer Institute), Christina M. Canil(University of Ottawa), Thomas Powles(National Health Service), Evan Ferrier, Neeraj Agarwal(University of Utah), Georg A. Bjarnason(Sunnybrook Health Science Centre), Benoit Beuselinck(Universitair Ziekenhuis Leuven)
Cited by 2
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k